博济医药
(300404)
| 流通市值：30.78亿 | | | 总市值：42.30亿 |
| 流通股本：2.81亿 | | | 总股本：3.86亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 361,448,457 | 138,861,747.84 | 742,019,124.54 | 556,148,773.73 |
| 营业收入 | 361,448,457 | 138,861,747.84 | 742,019,124.54 | 556,148,773.73 |
| 二、营业总成本 | 339,017,207.06 | 133,525,582.85 | 711,635,085.64 | 519,937,507.73 |
| 营业成本 | 250,680,746.54 | 96,368,429.87 | 516,629,157.81 | 377,140,098.56 |
| 税金及附加 | 3,362,885.66 | 1,206,376.71 | 6,914,185.11 | 5,305,161.39 |
| 销售费用 | 25,595,831.69 | 11,782,325.58 | 53,809,106 | 38,727,578.79 |
| 管理费用 | 35,509,416.35 | 14,529,635.19 | 70,633,027.32 | 53,418,372.24 |
| 研发费用 | 23,199,684.18 | 9,289,734.47 | 62,593,951.61 | 44,450,607.56 |
| 财务费用 | 668,642.64 | 349,081.03 | 1,055,657.79 | 895,689.19 |
| 其中:利息费用 | 901,597.45 | 509,095.34 | 3,186,407.41 | 2,560,897.37 |
| 其中:利息收入 | 316,426.73 | 205,526.25 | 2,300,564.7 | 1,799,050.78 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 914,273.99 | 490,581.85 | 1,058,690.69 | 980,609.38 |
| 加:投资收益 | 301,173.62 | 61,231.81 | 1,979,446.48 | 1,481,998.22 |
| 资产处置收益 | - | - | -213,678.75 | - |
| 资产减值损失(新) | -4,518,309.7 | -1,199,977.4 | -6,349,010.26 | -3,751,485.06 |
| 信用减值损失(新) | -8,848,206.87 | -3,344,588.25 | -17,543,157.35 | -11,882,335.6 |
| 其他收益 | 3,732,202.32 | 2,560,044.7 | 9,270,391.91 | 8,184,065.05 |
| 四、营业利润 | 14,012,383.3 | 3,903,457.7 | 18,586,721.62 | 31,224,117.99 |
| 加:营业外收入 | 1,932.3 | 11.85 | 44,805.46 | 45,041.32 |
| 减:营业外支出 | 160,392.36 | 60,381.7 | 212,030.13 | 105,911.39 |
| 五、利润总额 | 13,853,923.24 | 3,843,087.85 | 18,419,496.95 | 31,163,247.92 |
| 减:所得税费用 | -3,706,505.86 | -837,653.21 | -12,237,970.27 | -14,198,504.19 |
| 六、净利润 | 17,560,429.1 | 4,680,741.06 | 30,657,467.22 | 45,361,752.11 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 17,560,429.1 | 4,680,741.06 | 30,657,467.22 | 45,361,752.11 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 15,569,864.27 | 3,900,579.72 | 28,776,806.52 | 43,277,754.83 |
| 少数股东损益 | 1,990,564.83 | 780,161.34 | 1,880,660.7 | 2,083,997.28 |
| 扣除非经常损益后的净利润 | 11,988,298.74 | 1,697,920.67 | 19,304,628.89 | 34,889,757.75 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.04 | 0.01 | 0.08 | 0.11 |
| (二)稀释每股收益 | 0.04 | 0.01 | 0.08 | 0.11 |
| 八、其他综合收益 | -138,760.48 | -82,948.74 | 519,743.78 | -369,497.05 |
| 归属于母公司股东的其他综合收益 | -137,183.38 | -82,366.48 | 513,436.7 | -365,486.64 |
| 九、综合收益总额 | 17,421,668.62 | 4,597,792.32 | 31,177,211 | 44,992,255.06 |
| 归属于母公司股东的综合收益总额 | 15,432,680.89 | 3,818,213.24 | 29,290,243.22 | 42,912,268.19 |
| 归属于少数股东的综合收益总额 | 1,988,987.73 | 779,579.08 | 1,886,967.78 | 2,079,986.87 |
| 公告日期 | 2025-08-27 | 2025-04-26 | 2025-04-26 | 2024-10-26 |
| 审计意见(境内) | | | 标准无保留意见 | |